CNBC July 30, 2024
Key Points
– An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer’s disease by protecting patients’ brains, according to data from a mid-stage trial.
– Novo Nordisk sells liraglutide under the brand names Saxenda and Victoza, which are seeing sales decline as demand for the company’s weekly diabetes injection Ozempic and weight loss shot Wegovy skyrockets.
– The results add to growing evidence that the highly popular class of obesity and diabetes medications called GLP-1s may have significant health benefits beyond weight loss and regulating blood sugar.
An older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer’s disease by protecting patients’...
Today's Sponsors
Today's Sponsor